About NIH
NIH Leadership
- UPDATE
- 2025-01-07
- Deputy Minister,
National Institute of Health - Director General,
Department of Research
Planning and Coordination - Director General,
Department of Precision Medicine - Director General,
Department of Chronic Disease
Convergence Research - Director,
National Institute of
Infectious Disease - Director General,
Center for Emerging
Virus Research - Director General,
Center for Infectious Disease Research - Director General,
Center for Vaccine Research
Deputy Minister, National Institute of Health
Deputy Minister,
National Institute of Health Park, Hyun-Young.
- Education
-
- Bacelor of Medicine, Yonsei University, College of Medicine, Korea
- Master of Medicine, Yonsei University, College of Medicine, Korea
- Doctor of Medicine, Yonsei University, College of Medicine, Korea
- Career
-
- Assistant professor, Cardiovascular Research Institute
- Director, Division of Cardiovascular and Rare disease, Center for Biomedical Sciences, KNIH
- Director, Division of Cardiovascular, Center for Biomedical Sciences, KNIH
- Leader, Research team to respond to fine dust diseases, KCDC
- Leader, Patient information management team, KCDC headquarters
- Leader, Promotion team of National Center for Medical Information and Knowledge
- Leader, Clinical Research Support TF
- Clinical Research Benefit Evaluation Committee, Ministry of Health and Welfare
- Management Council, National Forensic Service
- Patient-centered medical technology optimization research project
- Director, Department of Precision Medicine
- Chief, National Biobank of Korea
Major Research Field
- Clinical mechanics & Genome
- Precision medicine
- Cardiovascular disease
- Women's health
Performance
- Use of Menstrual Sanitary Products in Women of Reproductive Age: Korea Nurses' Health Study(Osong Public Health Res Perspect, 2021)
- Evaluation of menopausal hormone therapy use in Korea (2002-2013): A nationwide cohort study. (Maturitas, 2021)
- The Korean Pregnancy Outcome Study (KPOS): Study Design and Participants(J Epidemiol, 2021) and 178 others
Message
.
Director General, Department of Research Planning and Coordination
Director General,
Department of Research Planning
and Coordination Jeong, youngki.
- Education
-
- -
- -
- -
- Career
-
- -
- -
Major Research Field
- -
- -
Performance
- -
- -
Message
-
Director General, Department of Precision Medicine
Director General,
Department of Precision Medicine Jeon, Jae-pil.
- Education
-
- -
- -
- -
- Career
-
- -
- -
Major Research Field
- -
Performance
- -
Message
.
Director General, Department of Chronic Disease Convergence Research
Director General,
Department of Chronic Disease
Convergence Research Kim, Won-ho.
- Education
-
- -
- -
- -
- Career
-
- -
- -
Major Research Field
- -
Performance
- -
Director, National Institute of Infectious Disease
Director,
National Institute of Infectious Disease Jang, Hee-chang.
- Education
-
- Seoul National University College of Medicine(Department of Medicine)
- Postdoc. fellowship, Department of Medicine Harvard Medical School, Massachusetts General Hospital(Division of infection diseases), USA
- Career
-
- Resident, Fellow, Seoul National University Hospital
- International Cooperation Doctor, Korea International Cooperation Agency(KOICA) (Bangladesh)
- Committee member, the National Examination for Medical Practitioners
- Vaccination committee, Korea Centers for Disease Control and Prevention(KCDC)
- Professor, Chonnam National University School of Medicine (Infectious Diseases)
- Chairman, the Institutional Review Board(IRB), KDCA
Major Research Field
- Antibiotic resistance
- Antibiotic therapy
- Emerging infectious diseases
- Vaccines
Performance
- Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009 Aug 1;49(3):395-401.
- A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Vaccine. 2010 Aug 16;28(36):5845-9.
- Active surveillance for carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit: Can it predict and reduce subsequent infections and the use of colistin Am J Infect Control. 2017 Jun 1;45(6):667-672. 3 other cases
Director General, Center for Emerging Virus Research
Director General,
Center for Emerging Virus Research Lee, Joo-yeon.
- Education
-
- Doctor of Science
- Career
-
- Director, Division of Emerging Disease and Vector Research, KCDC
- Leader, Promotion team for developing treatments, KCDC headquaters
Major Research Field
- A study on the development of control technologies such as diagnosis, treatment, and immunity of new, variant, and acute viral infectious diseases such as COVID-19, influenza, and SFTS.
Performance
- Published, The J2N-k hamster model simulates a severe SARS-CoV-2 infection in patients with cardiovascular diseases. (2022, J Virol Methods.)
- Published, Persistence of the neutralising antibody response after SARS-CoV-2 infection. (2021, Clin Microbiol Infect.) etc.
- Patent, Transgenic mouse expressing human DPP4 gene susceptible for South Korean strain Middle East respiratory syndrome coronavirus infection and use thereof(2021). etc.
Message
Center for Emerging Virus Research is developing treatments and control technologies for acute and chronic virus infectious diseases such as COVID-19, influenza, and AIDS, and strengthening the foundation for life cycle research through clinical brokerage research.
Director General, Center for Infectious Disease Research
Director General,
Center for Infectious Disease Research Chung, Gyeong-tae.
- Education
-
- Bachelor of Science, Chung Ang University, Department of biology
- Master of Science, Chung Ang University College of Medicine, Department of Microbiology
- Doctor of Science, Chung Ang University College of Medicine, Department of Microbiology
- Career
-
- Kyoto Prefectural University of Medicine
- OSAKA University of Medicine
- Johns Hopkins School of Medicine
- Thomas Jefferson University of medicine
- Health Protection England
- Director, Division of Waterborne diseases, KCDC
- Director, Division of microorganism, MFDS
- Director, Division of Vaccine research, KCDC
Major Research Field
- Tuberculosis
- Antibiotic Resistance
- Bacterial infectious disease such as zoonosis
- Development of core technologies for diagnosis, treatment, and infection control
- Support for the development of new technologies based on clinical linkage
Performance
- Published, Development of an attenuated smallpox vaccine candidate: The KVAC103 strain (2021, Vaccine)
- Published, Optimization of Zika DNA vaccine by delivery systems (2021, Vaccine) and 10 others
- Patent, RECOMBINANT ANTIGEN DERIVED FROM ZIKA VIRUS E PROTEIN AND USE THEREOF(2018) and 3 others
Message
In september 2020, with the opening of National Institute of Infectious Diseases (NIID), Center for Infectious Disease Research will be in charge of bacterial infectious diseases and will contribute to the improvement of public health by expanding and reorganizing the entire cycle of research and support.
Director General, Center for Vaccine Research
Director General,
Center for Vaccine Research Dokeun Kim.
- Education
-
- Korea University, Bachelor’s Degree (Department of Biology)
- Korea University, Master’s Degree (Department of Biology)
- Korea University, PhD, (Department of Biotechnology)
- Career
-
- Director for Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Health(KNIH)
- Senior Staff Scientist, Biologics Division, Ministry of Food and Drug Safety(MFDS)
Major Research Field
- 3rd generation smallpox vaccine and SFTS vaccine development & related basic research
- Vaccine research on emerging infectious diseases such as novel influenza, COVID-19, and mpox
- Next generation tuberculosis vaccine and mumps vaccine
- Vaccine-relevant new technology including mRNA
Performance
- (Nature Communications) Innate immune responses against mRNA vaccine promote cellular immunity through IFN-B at the injection site. 2024
- (Vaccines) Immunogenicity and cross-protection efficacy of a genotype F-derived attenuated virus vaccine candidate against mumps virus in mice. 2024
- (Frontiers in Immunology) In silico analysis for the development of multi-epitope vaccines against Mycobacterium tuberculosis. 2024
Type 4 : Source Indication - Commercial Use Prohibition - Change Prohibition The works of the Ministry of Science and ICT can be used under the terms of "KOGL Type 4".